Cytokine-based immunotherapy of allergic disease

• Authors: I.P. Lewkowich , K.T. HayGlass
• Languages of publication: EN

Abstracts

EN

Human immediate hypersensitivity diseases are strongly associated with an excessive type 2 response to normally innocuous environmental antigens, and are a growing health care concern in developed nations. Commonly prescribed treatments provide effective symptomatic relief, but are unable to consistently ameliorate the underlying cause of allergic disease: the excessive generation of allergen specific Th2 cells. IL-12 and IL-18 are potent inducers of type 1 immunity, and, as such, have been proposed as candidates for treatment of allergic diseases. This review critically assesses the potential of recombinant IL-12 and IL-18 immunotherapy to redirect both de novo and established allergic responses in animal models of human allergic disease to clinically protective immune responses.

Keywords

EN

ALLERGIC DISEASE; IMMEDIATE HYPERSENSITIVITY; IMMUNOTHERAPY

Discipline

• IMMUNOLOGY: IMMUNOLOGY

• Publisher: Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Archivum Immunologiae et Therapiae Experimentalis
• Year: 2001
• Volume: 49
• Issue: 4
• Pages: 293-302

Contributors

author

I.P. Lewkowich

author

K.T. HayGlass

• Document Type: REVIEW
• Publication order reference: I. P. Lewkowich, Department of Immunology, University of Manitoba, Winnipeg, Canada